In Vivo CRO Market By Indication (Blood Cancer, Solid Tumors and Other Indications), By Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX) and Other Models), and By Region - Market Trends, Analysis, and Forecast till 2030

The aging of the population has also contributed to the growth of the Oncology-based In-Vivo CRO market. Due to the growing number of targeted therapies in the oncology pipeline, the existence of numerous pipeline drugs, and the use of oncology-based In-Vivo CROs in the development of novel therapies for patient diagnosis, prevention, and treatment, the number of late-stage pipeline therapies increased from 711 in 2017 to 849 in 2018, representing a 19% increase. These factors are anticipated to further propel market growth. Statistics available from international government organizations show that, along with the creation of vaccines against infectious diseases, cancer is one of the most researched indications. A few more things have also been essential. in boosting the market for oncology-based In-Vivo CROs, such as federal funding for research projects, rising cancer treatment costs, and research proficiency, all of which are anticipated to drive the market to new heights. The North American Association of Central Cancer Registries (NAACCR) has data indicating that there might be 176 2450 new cancer cases in the US in 2019.